Otonomy, a late-stage biotech developing sustained-exposure treatments for ear diseases, filed on Friday with the SEC to raise up to $86 million in an initial public offering. Otonomy plans to submit an NDA in the 1H15 for its lead candidate, AuriPro, which recently completed Phase 3 trials for middle ear effusion during TTP surgery.
Otonomy’s second candidate is in Phase 2b trials for Ménière’s disease, and it has a preclinical treatment for tinnitus. Another ear disease biotech, Switzerland-based Auris Medical ( EARS ), filed to raise the same amount just two weeks ago. Auris is in Phase 3 development for acute inner ear tinnitus.
Help employers find you! Check out all the jobs and post your resume.
